Emerging role of epigenetics in stroke - Part 1: DNA methylation and chromatin modifications

Archives of Neurology

Volumn 67, Issue 11, 2010, Pages 1316-1322

  Qureshi, Irfan A ^a   Mehler, Mark F ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AZACITIDINE; BIOLOGICAL MARKER; BUTYRIC ACID; CURCUMIN; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; MG 98; PROCAINAMIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

BRAIN FUNCTION; BRAIN ISCHEMIA; CELL REGENERATION; CELL THERAPY; CELL VIABILITY; CELLULAR STRESS RESPONSE; CHROMATIN STRUCTURE; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DNA METHYLATION; DNA MODIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HISTONE CODE; HUMAN; INHERITANCE; LEARNING; MEMORY; MOLECULAR MODEL; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEOSOME; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; RISK; STROKE; TREATMENT PLANNING; TREATMENT RESPONSE;

ANIMALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; HISTONES; HUMANS; STROKE;

EID: 78149491805     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.275     Document Type: Review

References (50)

1. Lloyd-Jones D, Adams R, Carnethon M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-486.
2. Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke. 2009;40(3)(Suppl):S111-S114.
3. Mehler MF. Epigenetic principles and mechanisms underlying nervous system functions in health and disease. Prog Neurobiol. 2008;86(4):305-341.
4. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol. 2009;49:243-263.
5. Csoka AB, Szyf M. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med Hypotheses. 2009;73(5):770-780.
6. Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6(8):597-610.
7. Gluckman PD, Hanson MA, Buklijas T, Low FM, Beedle AS. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat Rev Endocrinol. 2009;5(7):401-408.
8. Sharma RP, Tun N, Grayson DR. Depolarization induces downregulation of DNMT1 and DNMT3a in primary cortical cultures. Epigenetics. 2008;3(2):74-80.
9. Endres M, Meisel A, Biniszkiewicz D, et al. DNA methyltransferase contributes to delayed ischemic brain injury. J Neurosci. 2000;20(9):3175-3181.
10. Endres M, Fan G, Meisel A, Dirnagl U, Jaenisch R. Effects of cerebral ischemia in mice lacking DNA methyltransferase 1 in post-mitotic neurons. Neuroreport. 2001;12(17):3763-3766.
11. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol. 2004;61(11):1652-1661. (Pubitemid 39463422)
12. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C - >T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology. 2002;59(4):529-536.
13. Giacomini PS, Shannon PT, Clarke JT, Jaigobin C. Fabry's disease presenting as stroke in a young female. Can J Neurol Sci. 2004;31(1):112-114.
14. Dobrovolny R, Dvorakova L, Ledvinova J, et al. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes: eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med. 2005;83(8):647-654. (Pubitemid 41176074)
15. Kusuhara T, Ayabe M, Hino H, Shoji H, Neshige R. A case of Prader-Willi syndrome with bilateral middle cerebral artery occlusion and moyamoya phenomenon [in Japanese]. Rinsho Shinkeigaku. 1996;36(6):770-773.
16. Chen M, Gavrilova O, Liu J, et al. Alternative Gnas gene products have opposite effects on glucose and lipid metabolism. Proc Natl Acad Sci U S A. 2005;102(20):7386-7391. (Pubitemid 40696387)
17. Freson K, Izzi B, Labarque V, et al. GNAS defects identified by stimulatory G protein alpha-subunit signalling studies in platelets. J Clin Endocrinol Metab. 2008;93(12):4851-4859.
18. Freson K, Jaeken J, Van Helvoirt M, et al. Functional polymorphisms in the paternally expressed XLalphas and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation. Hum Mol Genet. 2003;12(10):1121-1130. (Pubitemid 36622144)
19. Freson K, Izzi B, Jaeken J, et al. Compound heterozygous mutations in the GNAS gene of a boy with morbid obesity, thyroid-stimulating hormone resistance, pseudohypoparathyroidism, and a prothrombotic state. J Clin Endocrinol Metab. 2008;93(12):4844-4849.
20. Touzé E, Rothwell PM. Sex differences in heritability of ischemic stroke: a systematic review and meta-analysis. Stroke. 2008;39(1):16-23.
21. Hu CJ, Chen SD, Yang DI, et al. Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab. 2006;26(12):1519-1526.
22. Zhou HJ, Zhang HN, Tang T, et al. Alteration of thrombospondin-1 and -2 in rat brains following experimental intracerebral hemorrhage [published online February 5, 2010]. J Neurosurg. doi:10.3171/2010.1.JNS09637.
23. Xing C, Lee S, Kim WJ, et al. Neurovascular effects of CD47 signaling: promotion of cell death, inflammation, and suppression of angiogenesis in brain endothelial cells in vitro. J Neurosci Res. 2009;87(11):2571-2577.
24. Wilson ME, Westberry JM. Regulation of oestrogen receptor gene expression: new insights and novel mechanisms. J Neuroendocrinol. 2009;21(4):238-242.
25. Westberry JM, Prewitt AK, Wilson ME. Epigenetic regulation of the estrogen receptor alpha promoter in the cerebral cortex following ischemia in male and female rats. Neuroscience. 2008;152(4):982-989.
26. Sunday L, Osuna C, Krause DN, Duckles SP. Age alters cerebrovascular inflammation and effects of estrogen. Am J Physiol Heart Circ Physiol. 2007;292(5):H2333-H2340.
27. Langley B, Brochier C, Rivieccio MA. Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. Stroke. 2009;40(8):2899-2905.
28. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074-1080.
29. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693-705.
30. Cairns BR. The logic of chromatin architecture and remodelling at promoters. Nature. 2009;461(7261):193-198.
31. Gilardi F, Mitro N, Godio C, et al. The pharmacological exploitation of cholesterol 7alpha-hydroxylase, the key enzyme in bile acid synthesis: from binding resins to chromatin remodelling to reduce plasma cholesterol. Pharmacol Ther. 2007;116(3):449-472.
32. Shafaati M, O'Driscoll R, Björkhem I, Meaney S. Transcriptional regulation of cholesterol 24-hydroxylase by histone deacetylase inhibitors. Biochem Biophys Res Commun. 2009;378(4):689-694.
33. Fang S, Miao J, Xiang L, Ponugoti B, Treuter E, Kemper JK. Coordinated recruitment of histone methyltransferase G9a and other chromatin-modifying enzymes in SHP-mediated regulation of hepatic bile acid metabolism. Mol Cell Biol. 2007;27(4):1407-1424.
34. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature. 2009;460(7255):587-591.
35. Raval AP, Dave KR, Pérez-Pinzón MA. Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab. 2006;26(9):1141-1147.
36. Deguchi K, Clewing JM, Elizondo LI, et al. Neurologic phenotype of Schimke immunoosseous dysplasia and neurodevelopmental expression of SMARCAL1. J Neuropathol Exp Neurol. 2008;67(6):565-577. (Pubitemid 351787083)
37. Geiger S, Holdenrieder S, Stieber P, et al. Nucleosomes in serum of patients with early cerebral stroke. Cerebrovasc Dis. 2006;21(1-2):32-37.
38. Geiger S, Holdenrieder S, Stieber P, et al. Nucleosomes as a new prognostic marker in early cerebral stroke. J Neurol. 2007;254(5):617-623.
39. Muller S, Dieker J, Tincani A, Meroni PL. Pathogenic anti-nucleosome antibodies. Lupus. 2008;17(5):431-436.
40. Faraco G, Pancani T, Formentini L, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol. 2006;70(6):1876-1884. (Pubitemid 44771903)
41. Giffard RG, Han RQ, Emery JF, Duan M, Pittet JF. Regulation of apoptotic and inflammatory cell signaling in cerebral ischemia: the complex roles of heat shock protein 70. Anesthesiology. 2008;109(2):339-348.
42. Zhao YM, Chen X, Sun H, et al. Effects of histone deacetylase inhibitors on transcriptional regulation of the hsp70 gene in Drosophila. Cell Res. 2006;16(6):566-576. (Pubitemid 43920285)
43. Soriano FX, Papadia S, Bell KF, Hardingham GE. Role of histone acetylation in the activity-dependent regulation of sulfiredoxin and sestrin 2. Epigenetics. 2009;4(3):152-158.
44. Kim D, Frank CL, Dobbin MM, et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron. 2008;60(5):803-817.
45. Kang SK, Lee DH, Bae YC, Kim HK, Baik SY, Jung JS. Improvement of neurological deficits by intracerebral transplantation of human adipose tissue-derived stromal cells after cerebral ischemia in rats. Exp Neurol. 2003;183(2):355-366.
46. Lee TH, Yoon JG. Intracerebral transplantation of human adipose tissue stromal cells after middle cerebral artery occlusion in rats. J Clin Neurosci. 2008;15(8):907-912.
47. Miller CA, Sweatt JD. Covalent modification of DNA regulates memory formation. Neuron. 2007;53(6):857-869.
48. Plummer R, Vidal L, Griffin M, et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res. 2009;15(9):3177-3183.
49. Szyf M. Epigenetic therapeutics in autoimmune disease. Clin Rev Allergy Immunol. 2010;39(1):62-77.
50. Guan JS, Haggarty SJ, Giacometti E, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459(7243):55-60.